Li Mou Zheng
Founder bei AMOY DIAGNOSTICS CO., LTD.
Vermögen: 265 Mio $ am 31.03.2024
Profil
Li Mou Zheng is the founder of Amoy Diagnostics Co., Ltd., which was founded in 2008.
He currently holds the position of Chairman at Amoy Diagnostics Co., Ltd.
Additionally, Dr. Zheng is currently the Chairman at SinoPath Medical Investment (Beijing) Co., Ltd.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.09.2023 | 87 701 616 ( 22,06% ) | 265 Mio $ | 31.03.2024 |
Aktive Positionen von Li Mou Zheng
| Unternehmen | Position | Beginn |
|---|---|---|
| AMOY DIAGNOSTICS CO., LTD. | Founder | 21.02.2008 |
SinoPath Medical Investment (Beijing) Co., Ltd.
 SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Chairman | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMOY DIAGNOSTICS CO., LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
SinoPath Medical Investment (Beijing) Co., Ltd.
SinoPath Medical Investment (Beijing) Co., Ltd. Medical/Nursing ServicesHealth Services SinoPath Medical Investment (Beijing) Co., Ltd. engages in the third-party medical diagnostic genetics laboratory. It provides clinical genetic testing, consultation, and advisory services. Its products include cancer detection, remote pathology consultation, hereditary cancer detection, hereditary cardiovascular disease testing, single-gene genetic disease detection, susceptibility gene examination, and immunohistochemistry. The company was founded on June 30, 2013 and is headquartered in Beijing, China. | Health Services |
